MX2017012293A - Particulas de n-(5-ciano-4-((2-metoxietil)amino)piridin-2-il)-7-fo rmil-6-((4-metil-2-oxopiperazin-1-il)metil)-3,4-dihidro-1,8-nafti ridina-1 (2h)-carboxamida. - Google Patents
Particulas de n-(5-ciano-4-((2-metoxietil)amino)piridin-2-il)-7-fo rmil-6-((4-metil-2-oxopiperazin-1-il)metil)-3,4-dihidro-1,8-nafti ridina-1 (2h)-carboxamida.Info
- Publication number
- MX2017012293A MX2017012293A MX2017012293A MX2017012293A MX2017012293A MX 2017012293 A MX2017012293 A MX 2017012293A MX 2017012293 A MX2017012293 A MX 2017012293A MX 2017012293 A MX2017012293 A MX 2017012293A MX 2017012293 A MX2017012293 A MX 2017012293A
- Authority
- MX
- Mexico
- Prior art keywords
- methyl
- particles
- oxopiperazin
- naphthyridine
- methoxyethyl
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 4
- BHKDKKZMPODMIQ-UHFFFAOYSA-N N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N BHKDKKZMPODMIQ-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015000202 | 2015-03-25 | ||
| PCT/IB2016/051633 WO2016151500A1 (en) | 2015-03-25 | 2016-03-23 | Particles of n-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2- oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2h)-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017012293A true MX2017012293A (es) | 2018-01-09 |
Family
ID=55637404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012293A MX2017012293A (es) | 2015-03-25 | 2016-03-23 | Particulas de n-(5-ciano-4-((2-metoxietil)amino)piridin-2-il)-7-fo rmil-6-((4-metil-2-oxopiperazin-1-il)metil)-3,4-dihidro-1,8-nafti ridina-1 (2h)-carboxamida. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9802917B2 (https=) |
| EP (1) | EP3274349B1 (https=) |
| JP (1) | JP6696995B2 (https=) |
| KR (1) | KR102606643B1 (https=) |
| CN (1) | CN107406448B (https=) |
| AR (1) | AR104060A1 (https=) |
| AU (2) | AU2016238437B2 (https=) |
| CA (1) | CA2977326C (https=) |
| ES (1) | ES2803028T3 (https=) |
| MX (1) | MX2017012293A (https=) |
| PL (1) | PL3274349T3 (https=) |
| RU (1) | RU2720456C2 (https=) |
| TW (1) | TWI699206B (https=) |
| WO (1) | WO2016151500A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6585167B2 (ja) * | 2014-10-03 | 2019-10-02 | ノバルティス アーゲー | Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 |
| CN113234072B (zh) * | 2016-05-20 | 2022-11-04 | 江苏豪森药业集团有限公司 | Fgfr4抑制剂、其制备方法和应用 |
| CN107619388A (zh) | 2016-07-13 | 2018-01-23 | 南京天印健华医药科技有限公司 | 作为fgfr抑制剂的杂环化合物 |
| CA3075720A1 (en) * | 2017-10-02 | 2019-04-11 | Novartis Ag | Method for preparing a pharmaceutical product |
| CN110234649B (zh) * | 2017-10-31 | 2021-10-15 | 江苏豪森药业集团有限公司 | Fgfr4抑制剂的盐、晶体、制备方法及其用途 |
| WO2019085860A1 (zh) * | 2017-10-31 | 2019-05-09 | 江苏豪森药业集团有限公司 | Fgfr4抑制剂晶型及其制备方法 |
| CN109745321B (zh) * | 2017-11-08 | 2022-04-29 | 上海翰森生物医药科技有限公司 | 包含fgfr4抑制剂的药物组合物 |
| AU2020298246A1 (en) * | 2019-06-21 | 2022-01-27 | Terns Pharmaceuticals Inc. | Compounds for inhibiting FGFR4 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9420999D0 (en) | 1994-10-18 | 1994-12-07 | Smithkline Beecham Plc | Novel compounds |
| CA2261633A1 (en) | 1996-07-29 | 1998-02-05 | Banyu Pharmaceutical Co., Ltd. | Chemokine receptor antagonists |
| ES2241192T3 (es) | 1997-12-17 | 2005-10-16 | MERCK & CO., INC. (A NEW JERSEY CORP.) | Antagonistas del receptor de integrina. |
| AR015514A1 (es) | 1998-02-10 | 2001-05-02 | Novartis Ag | Compuesto de amida, proceso para su preparacion y composicion farmaceutica que lo contiene |
| EP1218336A2 (en) | 1999-09-20 | 2002-07-03 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| JPWO2003068753A1 (ja) | 2002-02-14 | 2005-06-02 | 小野薬品工業株式会社 | Ｎ−カルバモイル窒素含有縮合環化合物およびその化合物を有効成分として含有する薬剤 |
| US20060004010A1 (en) | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
| AU2003303231A1 (en) | 2002-12-20 | 2004-07-14 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
| US7098332B2 (en) * | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| WO2004080966A1 (ja) | 2003-03-14 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| EP1613322A4 (en) | 2003-04-11 | 2008-08-13 | Taigen Biotechnology Co Ltd | AMINOQUINOLINE COMPOUNDS |
| US7749999B2 (en) | 2003-09-11 | 2010-07-06 | Itherx Pharmaceuticals, Inc. | Alpha-ketoamides and derivatives thereof |
| CN101223167B (zh) | 2005-07-15 | 2011-08-31 | 弗·哈夫曼-拉罗切有限公司 | 杂芳基稠合的环状胺 |
| BRPI0620408B8 (pt) | 2005-12-21 | 2021-05-25 | Novartis Ag | derivados de pirimidinil aril uréia sendo inibidores de fgf, seus usos, e preparação farmacêutica |
| EP1976528A2 (en) | 2005-12-29 | 2008-10-08 | Janssen Pharmaceutica, N.V. | Prokineticin 2 receptor antagonists |
| KR20090008217A (ko) | 2006-03-10 | 2009-01-21 | 오노 야꾸힝 고교 가부시키가이샤 | 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제 |
| WO2007146230A2 (en) | 2006-06-14 | 2007-12-21 | Merck & Co., Inc. | Non-nucleoside reverse transcriptase inhibitors |
| CA2679268A1 (en) | 2007-03-09 | 2008-09-18 | Novartis Ag | Treatment of melanoma |
| WO2009079008A1 (en) | 2007-12-19 | 2009-06-25 | Yangbo Feng | Benzopyrans and analogs as rho kinase inhibitors |
| US20110172217A1 (en) | 2008-09-05 | 2011-07-14 | Shionogi & Co., Ltd. | Ring-fused morpholine derivative having pi3k-inhibiting activity |
| RU2561109C2 (ru) | 2008-12-19 | 2015-08-20 | Дженентек, Инк. | Соединения и способы применения |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| CA2761009A1 (en) | 2009-05-04 | 2010-11-11 | Plexxikon, Inc. | Compounds and methods for inhibition of renin, and indications therefor |
| US9556201B2 (en) | 2009-10-29 | 2017-01-31 | Glaxosmithkline Llc | Bicyclic pyridines and analogs as sirtuin modulators |
| CN102596916B (zh) | 2009-10-30 | 2015-06-17 | 诺瓦提斯公司 | 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲的n-氧化物 |
| KR20120130104A (ko) | 2010-02-01 | 2012-11-28 | 닛뽕 케미파 가부시키가이샤 | Ｇｐｒ119 작동약 |
| WO2011111880A1 (ko) | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| BR112013002112B1 (pt) | 2010-07-29 | 2021-04-06 | Rigel Pharmaceuticals, Inc. | Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição |
| JP5620417B2 (ja) * | 2011-02-07 | 2014-11-05 | 中外製薬株式会社 | アミノピラゾール誘導体を含む医薬 |
| AP2013007153A0 (en) | 2011-03-18 | 2013-09-30 | Lupin Ltd | Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| SMT202100451T1 (it) | 2012-07-11 | 2021-09-14 | Blueprint Medicines Corp | Inibitori del recettore di crescita dei fibroblasti |
| WO2014059214A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2906552B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| US20150290235A1 (en) | 2012-11-23 | 2015-10-15 | Ab Science | Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| EP3019491A4 (en) | 2013-07-09 | 2016-12-21 | Dana Farber Cancer Inst Inc | KINASEHEMMER FOR THE TREATMENT OF DISEASES |
| AR097455A1 (es) | 2013-08-28 | 2016-03-16 | Astellas Pharma Inc | Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo |
| MX378288B (es) | 2013-10-18 | 2025-03-10 | Eisai R&D Man Co Ltd | Inhibidores de pirimidina del fgfr4. |
| CA2928042C (en) | 2013-10-25 | 2022-05-10 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| CN105683188B (zh) * | 2013-10-25 | 2018-02-09 | 诺华股份有限公司 | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
-
2016
- 2016-03-18 US US15/073,766 patent/US9802917B2/en active Active
- 2016-03-23 WO PCT/IB2016/051633 patent/WO2016151500A1/en not_active Ceased
- 2016-03-23 KR KR1020177026470A patent/KR102606643B1/ko active Active
- 2016-03-23 PL PL16712082T patent/PL3274349T3/pl unknown
- 2016-03-23 EP EP16712082.3A patent/EP3274349B1/en active Active
- 2016-03-23 AU AU2016238437A patent/AU2016238437B2/en active Active
- 2016-03-23 RU RU2017133243A patent/RU2720456C2/ru active
- 2016-03-23 ES ES16712082T patent/ES2803028T3/es active Active
- 2016-03-23 JP JP2017549754A patent/JP6696995B2/ja active Active
- 2016-03-23 CA CA2977326A patent/CA2977326C/en active Active
- 2016-03-23 MX MX2017012293A patent/MX2017012293A/es active IP Right Grant
- 2016-03-23 AR ARP160100792A patent/AR104060A1/es unknown
- 2016-03-23 CN CN201680018234.6A patent/CN107406448B/zh active Active
- 2016-03-24 TW TW105109283A patent/TWI699206B/zh active
-
2019
- 2019-02-07 AU AU2019200936A patent/AU2019200936A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TWI699206B (zh) | 2020-07-21 |
| RU2017133243A3 (https=) | 2019-07-29 |
| EP3274349B1 (en) | 2020-04-22 |
| AU2019200936A1 (en) | 2019-02-28 |
| AU2016238437A1 (en) | 2017-08-17 |
| CA2977326A1 (en) | 2016-09-29 |
| AR104060A1 (es) | 2017-06-21 |
| BR112017016991A2 (pt) | 2018-04-10 |
| CN107406448B (zh) | 2021-03-09 |
| AU2016238437B2 (en) | 2018-11-08 |
| KR20170129758A (ko) | 2017-11-27 |
| EP3274349A1 (en) | 2018-01-31 |
| TW201641106A (zh) | 2016-12-01 |
| PL3274349T3 (pl) | 2020-10-05 |
| CA2977326C (en) | 2023-08-29 |
| JP2018509446A (ja) | 2018-04-05 |
| KR102606643B1 (ko) | 2023-11-28 |
| WO2016151500A1 (en) | 2016-09-29 |
| US9802917B2 (en) | 2017-10-31 |
| JP6696995B2 (ja) | 2020-05-20 |
| ES2803028T3 (es) | 2021-01-22 |
| RU2720456C2 (ru) | 2020-04-30 |
| RU2017133243A (ru) | 2019-04-05 |
| US20160304489A1 (en) | 2016-10-20 |
| CN107406448A (zh) | 2017-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017012293A (es) | Particulas de n-(5-ciano-4-((2-metoxietil)amino)piridin-2-il)-7-fo rmil-6-((4-metil-2-oxopiperazin-1-il)metil)-3,4-dihidro-1,8-nafti ridina-1 (2h)-carboxamida. | |
| IL268988B (en) | Solid formations of isoquinolinone derivatives, process for their preparation, compositions containing them and methods of use | |
| MX2025001503A (es) | Medios y metodo para preparar vectores virales y usos de los mismos | |
| IL266674A (en) | Preparations and methods for treating an opioid overdose | |
| MX2019001313A (es) | Composiciones farmaceuticas. | |
| PH12018501378A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| PH12018500947B1 (en) | Crystal form, preparation method and intermediate of dihydropyrido ring compound | |
| IL269036A (en) | TYK2 inhibitors, uses and methods for their production | |
| MX2018009773A (es) | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). | |
| GEAP202014670A (en) | Agents, Uses and Methods for the Treatment of Synucleinopathy | |
| MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
| SG10201902326XA (en) | Mk2 inhibitors and uses thereof | |
| GEAP202014858A (en) | New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| PH12018502714A1 (en) | Nicotine particles and compositions | |
| NZ732371A (en) | Solid state forms of fused heteroaromatic pyrrolidinones | |
| IL256350A (en) | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders | |
| MX2019002057A (es) | Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc. | |
| MX2017005281A (es) | Etil n-boc piperidinil pirazolo piridonas como inhibidores de janus quinasa. | |
| MX2015013419A (es) | Cianoetilpirazolo piridonas aciclicas como inhibidores de janus quinasa. | |
| MX2017002775A (es) | Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b. | |
| MX2024000004A (es) | Proteinas de fusion de inhibidor de tripsina urinaria (uti). | |
| WO2019078968A3 (en) | Cyclic compounds as immunomodulating agents | |
| EP3269733A4 (en) | Peptide derived from gpc3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells | |
| MX2019000246A (es) | Formas en estado solido del dimesilato de palbociclib. | |
| IN2014CH00840A (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |